To evaluate the significance of routinely reported 'equivocal' lymphovascular invasion (LVI) in prostatectomy specimens of patients with clinically localized prostate cancer.
Introduction
Determining the likelihood of prostate cancer recurrence after prostatectomy, and the need for, and timing of, further adjuvant treatment is a significant challenge in the postoperative management of clinically localized prostate cancer. Although a number of studies over the last decade have examined the impact of lymphovascular invasion (LVI) as a predictor of biochemical recurrence (BCR), its importance has been debated, with a recent systematic review unable to definitively establish LVI as an independent predictor of BCR after prostatectomy [1] . A number of subsequent studies that address this question, however, have established LVI as being an important, independent predictor of disease recurrence [2] [3] [4] [5] [6] [7] [8] and, in the context of other clinical and pathological variables, LVI status can assist in establishing the postoperative management of these patients.
Most commonly LVI is defined as the unequivocal presence of tumour cells within an endothelial-lined space, and routine reporting of definitive LVI is recommended by the International Society of Urological Pathology (ISUP) [9] . In a number of cases, however, whilst tumour cells appear to be present within lymphovascular spaces, the presence of crush artefact, tangential sectioning through a vessel, insufficient tumour cells, or the possibility that the morphological features represent retraction artefact (the presence of an artificial cleft surrounding a cluster of tumour cells usually created during tissue processing), prevent unequivocal diagnosis. Although a definitive diagnosis may be assisted by immunohistochemical staining for endothelial cell markers, in most laboratories this is not performed routinely, so in the absence of an unequivocal invasion, tumours are considered negative by most authors, with the loss of potentially useful prognostic information [4, 5, 8, 9] . Since 2005 at our institution, the presence of LVI in prostatectomy specimens has been routinely reported as equivocal or definitive, based on the presence or absence of potential confounding pathological artefacts respectively.
The aims of the present study were to evaluate the clinical significance of routinely reported equivocal LVI, and to determine the risk of recurrence in comparison with cohorts with definitive LVI or without LVI.
Materials and Methods
Consecutive patients with clinically localized prostate cancer treated with prostatectomy between February 2004 and April 2012 were identified from our prospectively collected prostate cancer database and analysed retrospectively. Patients for whom LVI (n = 313) status was not reported were excluded. Routine collection and analysis of pre-and postoperative clinical and pathological data had institutional review board approval.
Prostatectomy specimens were processed as previously described [10] . Briefly, the surgical specimen surface was inked, formalin-fixed, paraffin-embedded and processed in its entirety. The seminal vesicles were truncated at their base. After a 5-10-mm segment from the apical margin was obtained, the prostate was transversely sectioned perpendicular to the urethra at 4-mm intervals. Serial sections of the slices from the apical margins and the base were cut radially. Five micrometre sections were stained with haematoxylin and eosin and assessed by specialist uropathologists. More than 95% of the cases in the series were graded according to the ISUP 2005 recommendations. Tumour volume was calculated from digital images as previously described. LVI status recorded in our database was extracted electronically from the synoptic pathology reports [11] . Serum PSA level was measured at 3, 6 and 12 months, then yearly thereafter. The use of salvage therapy was recorded prospectively.
We defined LVI as the unequivocal presence of tumour cells in an endothelial-lined space and was characterized as positive, negative or equivocal [9] . Equivocal LVI is the presence of a cluster of tumour cells in a space that is favoured to be, but has not been confidently determined to represent invasion into the lumen of an endothelial-lined vessel. This may be attributable to tangential sectioning through a vessel, retraction artefact or crush artefact, or the presence of single or small numbers of cells that raises the possibility of displacement artefact during sectioning (Fig. 1) . Differentiation between lymphatics and blood vessels by immunohistochemistry was not performed routinely, nor used to clarify the nature of 'equivocal' invasion.
The relationship between LVI status and other clinicopathological factors was evaluated using a chi-squared statistic for categorical variables and the Mann-Whitney Utest for continuous variables as appropriate. To determine the impact of LVI status on BCR, Kaplan-Meier curves were generated and compared using the log-rank test, with followup censored at the date of the last recorded PSA in patients without recurrence. For the purpose of this study, BCR was defined as a single PSA reading of ≥0.2 ng/mL or a rising PSA below this level, which was judged by the treating physician to represent recurrent disease and led to the institution of salvage therapy. Multivariable Cox regression analysis was performed to identify independent predictors of BCR-free survival. All statistical analyses were performed using SPSS statistics v17.0. All tests were two-sided, with a P value <0.05 taken to indicate statistical significance.
Results
In total we identified 1 310 patients that met our inclusion criteria. Their median age was 62 years, and tumours were mostly organ-confined disease (69.3%) with the majority (78.0%) graded as Gleason sum 7. LVI was identified as definitively present in 82 patient specimens (6.3%), equivocal in 43 (3.3%) and absent in the remaining 1 185 (90.4%).
Overall, patients with equivocal LVI had similar clinical and pathological features to those with definitive LVI, with significantly higher preoperative serum PSA levels, more poorly differentiated tumours and higher rates of extraprostatic extension and/or seminal vesicle invasion compared with patients with no LVI (Table 1 ). In addition, tumours were significantly larger, with a similar positive surgical margin rate to the definitive LVI cohort.
Detailed follow-up data were available for 1 255 patients, of whom 249 (19.8%) experienced a PSA recurrence, with a mean follow-up time of 31 months. In patients negative for LVI, 14.7% experienced BCR, vs 61.0% of patients with equivocal LVI and 71.0% of patients who had definitive LVI. Kaplan-Meier curves of BCR-free survival stratified by LVI status are shown in Fig. 2 . Consistent with recent reports, patients positive for LVI had a significantly shorter BCR-free survival time compared with those in whom LVI was absent. Interestingly, patients with equivocal LVI had an intermediate recurrence rate, which was significantly different from that of patients with no LVI (log-rank P < 0.001), but not that of patients in whom LVI was definitively present (log-rank P = 0.098). The relative importance of LVI status in predicting disease recurrence compared with other well established clinical and pathological predictors was determined by (Table 2) . Again, the presence of either definitive or 'equivocal' LVI, was an independent predictor of disease recurrence, although the magnitude of the effect was lower in the latter (hazard ratio [HR] 3.32, 95% CI 2.3-4.8; P < 0.001 vs HR 1.66, 95% CI 1.05-2.65; P = 0.032, respectively). To measure the inter-observer variability in LVI reporting, a random sample of cases with both definitive and equivocal LVI (n = 21) was reviewed by an independent pathologist blinded to the original designation. As shown in Table S1 , 80% of patients with routinely reported equivocal LVI were re-reported as equivocal on review, with the remainder being upgraded to definitive LVI. This concordance was similar to that of definitive LVI.
Discussion
Access to the systemic circulation by tumour cells is an important step in the dissemination of metastases to distant sites. LVI, where tumour cell emboli are observed directly within lymphatic and/or vascular spaces in the primary tumour, is the pathological equivalent of the detection of circulating tumour cells or tumour cell clusters in the blood and, as such, should be associated with an inherently increased risk of disease dissemination and recurrence a priori. It is therefore not surprising that LVI has been shown to be an independent predictor of poor prognosis in many of the most prevalent cancers, including urothelial cancers [12, 13] , rectal cancer [14] , gastric cancer [15, 16] , melanoma [17] , invasive breast cancer [18] , nonsmall-cell lung cancer [19, 20] and hepatocellular carcinoma [21] . As previously seen with prostate cancer there are varying results for oesophageal cancer [22, 23] . Reporting of LVI in the pathological assessment is recommended in all of the above-mentioned cancers to assist in risk stratification.
Historically, studies investigating the role of LVI in the prognosis of prostate cancer have been less definitive, with conflicting results attributable to heterogeneity in study design, including varying characteristics of study populations, study size, and definitions of LVI and of disease progression [1] ; however, more recent studies show that LVI in prostatectomy specimens is uniformly associated with adverse pathological features and an increased risk of disease recurrence after definitive treatment, and routine reporting in prostatectomy specimens is recommended by the ISUP. Consistent with these, we have confirmed that, although definitive LVI was present in <10% of cases, patients in whom it was identified had significantly worse pathological features as well a significantly lower BCR-free survival time compared with patients in whom LVI was absent.
In a number of cases, as a result of processing artefact or the presence of only a small number of tumour cells, it can be difficult to make a definitive diagnosis of LVI. Options in these circumstances include the use of immunohistochemical stains for endothelial markers to confirm that spaces surrounding tumour cell clusters are indeed lymphatic or vascular channels, which is not routinely performed, or reporting the LVI status as negative, as is commonly promulgated, with the loss of potentially useful information. An alternative is to recognize these cases as distinct entities, 'equivocal' LVI, in which true LVI is suspected by the reporting pathologist, but the presence of confounding features precludes a definitive diagnosis.
In the present series we have shown that patients with equivocal LVI have an almost equivalent distribution of adverse pathological features to that of patients with definitive LVI, as well as a rate of BCR that essentially mirrors that of tumours with unequivocal invasion. Importantly, even when adjusted for preoperative PSA level, tumour stage, grade and margin status, both LVI and equivocal LVI were significant independent predictors of disease recurrence, suggesting that routine reporting of equivocal LVI imparts prognostic information that would otherwise be lost.
The present study did not address the provenance of the vessels, either lymphatic or vascular, within which tumour cell invasion was assessed to have occurred. In other tumour types, such as breast cancer, both LVI and lymphatic vessel density correlate significantly with rates of metastasis [24, 25] . In breast cancer, axillary lymph node status is a prognostic indicator of patient outcomes. It is perhaps not surprising that LVI correlates with lymphatic vessel density and is, in effect, an early marker of axillary lymph node status in patients with high-risk breast cancer. It will be very interesting to determine whether any such association with lymphatic vessel invasion as opposed to vascular invasion is associated with metastasis in patients with prostate cancer.
There are several limitations to this study that deserve consideration. Although the data were collected prospectively, they were analysed retrospectively, which may have introduced selection bias. In addition, the mean follow-up period of 31 months may be insufficient to evaluate BCR, especially in pT2 disease, although overall 71% and 61% of patients with definitive and equivocal LVI, respectively, had experienced BCR by this time. As this was a real-world study, in cases of ambiguity, no attempt was made to clarify LVI status with the use of immunohistochemical markers. In addition, the vast majority of patients in this series did not undergo pelvic lymph node dissection. As LVI is associated with nodal spread, it is unclear if inclusion of nodal status as a term in the multivariable model would reduce the effect size of LVI (definitive or equivocal) on BCR.
In conclusion, LVI was an independent predictor of BCR in our cohort of patients with clinically localized disease treated with prostatectomy, and should continue to be included in routine pathology reporting for prostatectomy specimens. Our results suggest that consideration should also be given to reporting 'equivocal' LVI, as at least in the present study, equivocal LVI status confers similar adverse prognostic implications to those of definitive LVI; however, confirmation in an independent cohort is required before routine reporting can be recommended. 
Supporting Information
Additional Supporting Information may be found in the online version of this article: Table S1 . Interobserver concordance for reporting definitive and equivocal LVI determined by independent blinded review.
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